Morgan Stanley Purple Biotech Ltd. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	BUY	$0.41 - $0.86 $27,219 - $57,095	66,390 Added 48.6%	203,000 $83,000
Q2 2024 Aug 14, 2024	BUY	$0.41 - $0.86 $27,219 - $57,095	66,390 Added 48.6%	203,000 $83,000
Q1 2024 Oct 17, 2024	SELL	$0.58 - $0.92 $38,506 - $61,078	-66,390 Reduced 32.7%	136,610 $91,000
Q1 2024 Aug 16, 2024	BUY	$0.58 - $0.92 $29,056 - $46,089	50,097 Added 57.91%	136,610 $91,000
Q1 2024 May 15, 2024	BUY	$0.58 - $0.92 $29,056 - $46,089	50,097 Added 57.91%	136,610 $91,000
Q4 2023 Aug 16, 2024	SELL	$0.78 - $1.67 $90,859 - $194,533	-116,487 Reduced 57.38%	86,513 $67,000
Q4 2023 Feb 13, 2024	BUY	$0.78 - $1.67 $43,768 - $93,708	56,113 Added 184.58%	86,513 $67,000
Q3 2023 Nov 15, 2023	BUY	$1.02 - $1.49 $783 - $1,144	768 Added 2.59%	30,400 $36,000
Q2 2023 Aug 14, 2023	BUY	$1.38 - $2.05 $9,030 - $13,415	6,544 Added 28.34%	29,632 $41,000
Q1 2023 May 15, 2023	BUY	$1.36 - $2.3 $1,656 - $2,801	1,218 Added 5.57%	23,088 $41,000
Q4 2022 Feb 14, 2023	BUY	$1.38 - $2.22 $7,727 - $12,432	5,600 Added 34.42%	21,870 $30,000
Q3 2022 Nov 14, 2022	SELL	$1.9 - $2.69 $950 - $1,345	-500 Reduced 2.98%	16,270 $33,000
Q2 2022 Oct 27, 2022	BUY	$2.39 - $4.15 $21,359 - $37,088	8,937 Added 114.09%	16,770 $40,000
Q2 2022 Aug 15, 2022	BUY	$2.39 - $4.15 $21,359 - $37,088	8,937 Added 114.09%	16,770 $40,000
Q1 2022 Oct 27, 2022	SELL	$2.45 - $4.3 $21,895 - $38,429	-8,937 Reduced 53.29%	7,833 $31,000
Q1 2022 May 13, 2022	SELL	$2.45 - $4.3 $38,202 - $67,049	-15,593 Reduced 66.56%	7,833 $31,000
Q4 2021 Feb 14, 2022	SELL	$3.75 - $4.67 $502 - $625	-134 Reduced 0.57%	23,426 $91,000
Q3 2021 Nov 15, 2021	BUY	$4.4 - $5.59 $103,664 - $131,700	23,560 New	23,560 $108,000

Others Institutions Holding PPBT

# of Institutions

Shares Held

19.3K

Call Options Held

Put Options Held

View Full List

About PURPLE BIOTECH LTD.

Ticker PPBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,303,300
Market Cap $46.5M
Description
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...

More about PPBT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account